Hepatic Cell News 4.18 May 22, 2020 | |
| |
TOP STORYTFEB Regulates Murine Liver Cell Fate during Development and Regeneration Scientists showed that during development and upon regeneration, transcription factor EB drove the differentiation status of murine liver pluripotent stem cells into the progenitor/cholangiocyte lineage while inhibiting hepatocyte differentiation. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)The authors discovered that in the early stage of fatty liver disease, sphingosine 1-phosphate receptor 2-mediated neutrophil activation played an important role in the evolvement of liver injury. [Cell Death Dis] Full Article In vitro depletion and overexpression experiments showed that decreased β-arrestin2 inhibited hepatic stellate cells’ collagen production and elevated TβRIII expression, thus downregulating the TGF-β1 pathway components Smad2, Smad3 and Akt. [Cell Death Dis] Full Article Establishment of Rat Liver Cancer Cell Lines with Different Metastatic Potential Two liver cancer cells were obtained from N-nitrosodiethylamine and N-nitrosomorpholine induced rats. They were cultivated, screened and cloning cultivated. Bionomics of cells was analyzed and results showed that the two cells had different metastatic potentiality. [Sci Rep] Full Article The Hepatic Plasma Membrane Citrate Transporter NaCT (SLC13A5) as a Molecular Target for Metformin The authors reported that metformin inhibited the expression of the plasma membrane citrate transporter NaCT in hepg2 cells and decreased the cellular levels of citrate. [Sci Rep] Full Article Investigators indicated that the ROS/CREB/-miR-630 axis played a relevant role in the regulation of RAD18 and MCM8 in homologous recombination repair, which facilitated understanding of molecular mechanisms regarding the role of miR-630 downregulating DNA damage repair in liver cells. [Toxicology] Abstract Scientists demonstrated for the first time that oral administration of gigantol potently relieved liver oxidative stress and inflammation, possibly via a novel mechanism of inhibiting the C5b-9 formation in the liver. [Acta Pharmacol Sin] Abstract Arenobufagin had a significant anti-hepatoma effect in vitro and therapeutic effect on zebrafish xenograft model, regulating lipid homeostasis. Activated SM synthase and arginine deiminase inhibited sphingomyelinase, amino acid supply and JAK-STAT3 signaling pathway. [J Ethnopharmacol] Abstract | Graphical Abstract Using immortalized hepatocytes derived from fucosyltransferase 8 knockout mice, scientists found that loss of core fucose in immortalized hepatocytes led to low-density lipoprotein receptor downregulation through a dramatic induction of proprotein convertase subtilisin/kexin type 9. [Biochem Biophys Res Commun] Abstract 14,15β-Dihydroxyklaineanone Inhibits HepG2 Cell Proliferation and Migration Through p38MAPK Pathway Researchers found that 14,15β-dihydroxyklaineanone inhibited the growth and migration of HepG2 cells but did not induce cell apoptosis. 14,15β-dihydroxyklaineanone induced S cell cycle arrest by downregulating the expression levels of cyclin A, p-CDK2, cyclin B1, p21, E2F-1 and PCNA. [J Pharm Pharmacol] Abstract Visfatin increased the expression of CC chemokine ligand 20 (CCL20) via the NF-κB and MKK3/6-p38 signaling pathways in macrophages, and visfatin-induced CCL20 expression promoted the fibrosis markers in hepatic stellate cells. [Mol Biol Rep] Full Article Regulation of Bile Duct Epithelial Injury by Hepatic CD71+ Erythroid Cells In co-culture experiments, CD71+ erythroid cells suppressed the activation of hepatic mononuclear cells. Researchers uncovered an immunoregulatory role for CD71+ erythroid cells in the neonatal liver. [JCI Insight] Abstract | Graphical Abstract Subscribe to one of our other 19 science newsletters such as Intestinal Cell News & Pancreatic Cell News. | |
| |
REVIEWSUncovering the PIDDosome and Caspase-2 as Regulators of Organogenesis and Cellular Differentiation Newly established functions of the PIDDosome and its downstream effector render its components attractive targets for drug-development aiming to prevent fatty liver diseases, neurodegenerative disorders or osteoporosis. [Cell Death Differ] Full Article Non-Coding RNAs: Regulating Disease Progression and Therapy Resistance in Hepatocellular Carcinoma The authors provide a comprehensive description of the biological roles of non-coding (nc) RNAs in disease process and therapy resistance, and potential clinical application of these ncRNAs in hepatocellular carcinoma. [Cancers] Full Article Visit our reviews page to see a complete list of reviews in the hepatic cell research field. | |
| |
INDUSTRY NEWSCan-Fite BioPharma Ltd. have announced additional findings from its Phase II study of Namodenoson in the treatment of patients with non-alcoholic fatty liver disease with or without non-alcoholic steatohepatitis. [Can-Fite BioPharma Ltd.] Press Release Can-Fite BioPharma Ltd. have also announced that the US Patent and Trademark Office has issued a Notice of Allowance for their patent titled, “Method for treating NASH accompanied by fibrosis using CI-IB-MECA”. [Can-Fite BioPharma Ltd.] Press Release | |
| |
POLICY NEWSWill Trump White House Tear Down Journal Paywalls? Many Anxiously Await a Decision Scientific publishers, universities, librarians, and open-access advocates are waiting anxiously to see whether the Trump administration will end a long-standing policy and require that every scholarly article produced with US funding be made immediately free to all. [ScienceInsider] Editorial Are Women Publishing Less during the Pandemic? Here’s What the Data Say Early analyses suggest that female academics are posting fewer preprints and starting fewer research projects than their male peers. [Nature News] Editorial
| |
EVENTSIn light of COVID-19, many conferences are being cancelled or postponed. As such: We are suspending new event postings in our newsletters and on Twitter. Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Assistant or Associate Professor – Pharmacology & Toxicology (University of Southern California) Postdoctoral Fellowships – Liver Research (The University of Hong Kong) Postdoctoral Scientist – Quantitative Biology (Texas Biomedical Research Institute) Research Scientist – Liver (Spark Therapeutics) Staff Fellow – Viral Vaccines (FDA-Center for Biologics Evaluation and Research) Postdoctoral Fellow – Molecular Diagnostics and Experimental Therapeutics (City of Hope) Professorship of Hepatology (Ludwig-Maximilians-Universität) Scientist – Molecular & Cellular Biology (Deep Genomics, Inc.) Postdoctoral Position – Gut-Liver Axis (University of California, Davis) Therapuetic Specialist – Inflammation (Gilead Sciences Inc.) Team Leader – Cholangiocytes (Miromatrix Medical) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hepatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|